Release – ProMIS Neurosciences (ARFXF)(PMN:CA) – Completes US$7M (CDN$8.75M) Financing


ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors

 

TORONTO, Ontario and CAMBRIDGE, Mass. — March 22, 2021— ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce today the completion of an US$7M (CDN$8.75M) private placement of convertible unsecured debentures (the “Debentures“).

The investors include Mike Gordon of Fenway Sports Group, the Kraft Group, Henry McCance, co-founder of the Cure Alzheimer’s Fund, and Jeremy Sclar of WS Development Group. “After conducting diligence with a number of experts in the field, we are impressed with the tremendous potential of ProMIS Neurosciences and its unique platform of drug candidates to have a profound impact in the fight against Alzheimer’s and other neurodegenerative diseases.  Our group is pleased to provide funding for the next phase of the company’s exciting future”, stated Mike Gordon of Fenway Sports Group.

“We are honored to have the support of such a distinguished group of investors, all of whom are accomplished leaders in the business and life sciences arenas” said Gene Williams, ProMIS Executive Chairman.

Debenture Terms

The Debentures are convertible into ProMIS common shares at the option of the holder at a conversion price of US$0.10 per share and accrue interest at 1% per annum, which is payable annually. At the company’s election, accrued interest may be paid in cash or common shares (such number of shares determined by dividing the interest due by the 5-day volume-weighted average trading price or “VWAP” of the common shares).

The Debenture mature on March 22, 2026. Prior to the maturity date, the Company may force conversion of the Debentures at the conversion price upon raising US$50M in equity and/or debt cumulatively. On the maturity date, the Company may redeem the outstanding principal amount of the Debentures in either cash or common shares (at the then 5-day VWAP less a 10% discount) or a combination thereof at its election. Amounts redeemed in common shares on the Maturity Date will be subject to TSX acceptance.

The investors were granted a right to participate, on a pro rata basis, in subsequent company offerings of equity securities for cash consideration pursuant to a public offering or a private placement.

The Debentures and any common shares issued on conversion are subject to a four-month hold period that expires on July 22, 2021. Net proceeds will be used for working capital and general corporate purposes.

ProMIS plans to accelerate progress toward a number of top priorities, including:

  • Advancing the PMN310 monoclonal antibody, our potential “best in class” next generation Alzheimer’s treatment, into clinical testing;
  • Enhancing our partnering prospects for programs under active discussion by allowing us to invest in additional validation data; 
  • Expanding our portfolio of products and intellectual property into new target areas, using our proprietary discovery platform; 
  • Advancing our partnered diagnostic programs; 
  • Achieving NASDAQ listing;
  • Expanding our Board of Directors; and
  • Expanding our management team, capitalizing on the talent pool in Boston, to support a growing and ambitious scope of activity.

Retirement of our CEO

Finally, a note of great appreciation for our CEO, Dr. Elliot Goldstein.   Elliot, who just turned 70, has announced his intention to retire from a full time role by the end of 2021.   Even though Elliot is irreplaceable, ProMIS has initiated a search for a new CEO to help us achieve our potential.   “Elliot has been a close friend and valued business partner for decades,” said Gene Williams, “without his significant contributions, we would not have been able to take ProMIS from just a great science idea to a company with a growing portfolio of therapies that have the potential to be life-altering for patients.   On behalf of the entire ProMIS community, and patients who in the future may benefit from our therapies, I offer Elliot our sincere thanks and gratitude”.   

“ProMIS Neurosciences was launched six years ago based on a world class scientific platform from our CSO and scientific founder, Dr. Neil Cashman. Playing a key role in this endeavor has been one of the most challenging yet rewarding experiences of my 40 odd years in pharmaceutical drug development. I am delighted for this exciting new phase of the Company”, stated Dr. Elliot Goldstein, ProMIS CEO.

About ProMIS Neurosciences 

ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s disease, the DSEs are misfolded regions on toxic forms of otherwise normal proteins.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF. 

Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn. 

For Investor Relations please contact: 

Alpine Equity Advisors 
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Source:

ProMIS Neurosciences


Release – Lineage Cell Therapeutics (LCTX) – Presents Additional Interim Data On Opregen For Dry Amd With Geographic Atrophy

 


Lineage Cell Therapeutics Presents Additional Interim Data On Opregen® For Dry Amd With Geographic Atrophy

 

  • Seventy-Five Percent of All Cohort 4 Patients Have Experienced BCVA Increases
  • Visual Acuity Continues to Decline in the Majority of Untreated Eyes
  • No Acute or Delayed Inflammation or Rejection of OpRegen Observed, Even in Patients Treated with a Reduced Immunosuppressive Regimen

CARLSBAD, Calif.–(BUSINESS WIRE)–Mar. 23, 2021– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced new positive interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). Additional interim data were collected on all 24 patients enrolled in the study, including the 12 patients treated in Cohort 4, which feature less advanced disease, better baseline visual acuity, and smaller areas of GA.

Overall, 9/12 (75%) of the Cohort 4 patients’ treated eyes were at or above baseline visual acuity at their last assessment, based on per protocol scheduled visits ranging from 3 months to > 2 years post- transplant. Improvements in best corrected visual acuity (BCVA) reached up to +19 letters on an EDTRS chart. In contrast, 9/12 (75%) of the patients’ untreated eyes were below baseline entry values at the same time points. Among the newly reported data, three (50%) of the more recently treated Cohort 4 patients have exhibited marked improvements in BCVA ranging from +7 to +16 letters at their last scheduled assessments of at least 4.5 months. Two additional Cohort 4 patients remained within 2 letters of their baseline values (one each above and below). One patient measured 7 letters below baseline.

Previously reported structural improvements in the retina and decreases in drusen density have continued with evidence of durable engraftment of OpRegen cells in some treated patients now extending to more than 5 years in the earliest treated patients. A trend towards slower GA progression in treated compared to fellow eyes also continued, although significant changes in GA growth over a 3-month period following treatment are not expected. Overall, OpRegen has been well tolerated with no unexpected adverse events or serious adverse events.

“Data collected from the six additional Cohort 4 patients which we treated last fall has reinforced our prior results and further supports that treatment with OpRegen may provide clinically meaningful outcomes in dry AMD patients with GA. Improvements in BCVA have become apparent within a few months after dosing, consistent with the predicted activity of an RPE cell transplant,” stated  Brian M. Culley, Lineage CEO. “If these early indications of a treatment effect are maintained or improve further, it will be another positive indicator for the potential of OpRegen to improve outcomes in this condition. We continue to monitor all patients on study and in the coming months we will be looking in particular for indications of retinal restoration, reductions in the size and growth of the areas of GA, and functional improvement in visual acuity. Further, the multi-year stability of OpRegen transplants, some in excess of 5 years without signs of rejection, is notable for the durability of our allogeneic cell therapy approach, especially as patients did not require long-term immunosuppression.”

As part of an ongoing effort to administer the minimally effective dose and duration of immunosuppression, reflecting the COVID pandemic and age of typical AMD patients while ensuring the survival of OpRegen cells, no immunosuppression was utilized beyond the perioperative period of up to 3 months in Cohort 4 patients. Notably, the one OpRegen patient who had received a modified immunosuppressive regimen at baseline which included no tacrolimus and only mycophenolate mofetil, does not show any signs of acute or delayed inflammation or rejection of OpRegen cells. One other patient was diagnosed with COVID shortly after treatment with OpRegen and all immunosuppression was halted and then reinstated once the patient was asymptomatic. This second patient similarly showed no signs of acute or delayed inflammation or rejection of OpRegen cells. Other than the reduced regiments described above, immunosuppressants have been discontinued as scheduled, typically within 90 days post-operatively, and no cases of acute or delayed rejection or inflammation due to OpRegen have been reported.

Additional details regarding this data will be presented as part of a corporate update by  Mr. Culley at the Benzinga Global Biotech Small Cap conference on 
March 24, 2021 at 
11:50am Eastern Time / 
8:50am Pacific TimeMr. Culley will also be participating in a panel entitled “Coming Together to Address Unmet Medical Needs,” on 
March 24, 2021 at 
12:50pm Eastern Time / 
9:50am Pacific Time. Interested investors are encouraged to register for the event in advance: https://www.benzinga.com/events/small-cap/biotech/. The live and archived webcasts from the event will be available on the Events and Presentations section of Lineage’s website. Additional videos are available on the Media page of the Lineage website.

About OpRegen

OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. The study enrolled 24 patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort enrolled 12 better vision patients (vision from 20/65 to 20/250 with smaller areas of GA). Cohort 4 also included patients treated with a new “thaw-and-inject” formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. The primary objective of the study is to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. Additional objectives include the evaluation of the safety of delivery of OpRegen using the Orbit SDS, manufactured by 
Gyroscope Therapeutics, Ltd.

OpRegen is a registered trademark of 
Cell Cure Neurosciences Ltd., a majority-owned subsidiary of 
Lineage Cell Therapeutics, Inc.

About Dry AMD

Dry age-related macular degeneration (AMD) is a leading cause of adult blindness in the developed world. There are two forms of AMD: wet AMD and dry AMD. Dry AMD is the more common of the two types, accounting for approximately 85-90% of cases. Wet AMD is the less common of the two types, accounting for approximately 10-15% of cases. Global sales of the two leading wet AMD therapies were in excess of 
$10 billion in 2019. Nearly all cases of wet AMD begin as dry AMD. Dry AMD typically affects both eyes. There are currently no 
U.S. Food and Drug Administration (FDA) or 
European Medicines Agency (EMA) approved treatment options available for patients with dry AMD.

About Lineage Cell Therapeutics, Inc. 

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the expected clinical outcomes of dry AMD patients with GA and the expected timing when indications of retinal and reductions in size and expansion of the areas of GA may become apparent. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the 
Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the 
SEC, including Lineage’s most recent Annual Report on Form 10-K filed with the 
SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa
(Gogawa@troutgroup.com)
(646) 378-2949

Russo Partners – Media Relations
Nic Johnson or David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Source: Lineage Cell Therapeutics, Inc.

Research coverage of Lineage Cell Therapeutics (LCTX) on Channelchek is provided by Noble Capital Markets, Inc. Please refer to the research disclosures on the most recent LCTX report for more information.

QuickChek – March 23, 2021



Allegiant Gold Announces Participation in Noble Capital Markets Virtual Road Show Series

Allegiant Gold announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for March 25, 2021.

Research, News & Market Data on Allegiant Gold

Watch recent C-Suite interview with Allegiant Gold CEO Peter Gianulis



ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing

ProMIS Neurosciences announced the completion of an US$7M (CDN$8.75M) private placement of convertible unsecured debentures

Research, News & Market Data on ProMIS Neurosciences




electroCore Announces Exclusive Distribution Agreement with Silvert Medical Nv-Sa.

electroCore Inc. announced it has entered into an agreement whereby Silvert Medical will serve as the exclusive Western European distributor of the gammaCore Sapphire non-invasive vagus nerve stimulator

Research, News & Market Data on electroCore



Lineage Cell Therapeutics Presents Additional Interim Data On Opregen For Dry Amd With Geographic Atrophy

Lineage Cell Therapeutics announced new positive interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen

Research, News & Market Data on Lineage Cell Therapeutics

Watch recent presentation from NobleCon17



Comstock and MCU Commence Philippine Mercury Remediation Operations

Comstock Mining announced that its first international remediation and extraction facility is now in production

Research, News & Market Data on Comstock Mining

Watch recent interview with Comstock Mining CEO Corrado De Gasperis

Stay up to date. Follow us:

How close is the U.S. to Having a Digital Currency?


What’s the Timeline for a U.S. Digital Currency?

 

Investment opportunities related to the adoption of a U.S. digital currency will undoubtedly change fortunes. But will we ever adopt crypto and are we even close? Actions by the Federal Reserve taken last year and a crescendo of recent statements from top officials suggests that it’s in the works. So the question is “When?” “In what form” and “Who stands to benefit from a Fedcoin?”

Central Bank
Digital Currencies (CBDC) Exploratory Phase

The Federal Reserve Bank of Boston has been collaborating with MIT on what they call the Digital Currency Initiative. They have been exploring together the use of existing and new technologies to build and test a digital currency platform. This includes assessing technology trade-offs, building a hypothetical CBDC, building scalable architecture, a cryptographic platform able to meet the needs of a digital U.S. dollar, speed, security, privacy, and flexibility. Separate from its collaboration with MIT the Boston Fed is evaluating other systems to better comprehend the pros and cons of the U.S. banking system supporting a CBDC.

In a panel discussion yesterday for the Bank of International Settlements (March 22, 2021), Fed Chair Powell exposed some of the Fed’s current thinking. He indicated that when it came to a CBDC, the U.S. has “an obligation to be on the cutting edge of understanding the technological challenges.” He also made clear that any expected benefits of a digital dollar wouldn’t rush the project and that the Fed wouldn’t proceed without support from Congress, preferably in the form of legislation.

The Federal Reserve Bank of Boston, Senior Vice President James Cunha who serves as a spokesman for this project has said the Boston Fed and MIT hope to unveil some of their work in the third quarter of 2021. This includes at least two prototype software platforms that could move, store, and settle transactions made with digital dollars. He did not say if either platform uses the blockchain technology that underlies other cryptocurrencies such as Bitcoin or Ethereum. Once the prototypes are released, Cunha said, others will be able to look at what was built and experiment with the open-source code.

The Fed’s work is intended to show what’s possible without taking a position on the major issues that are out of the purview of the Boston Fed.  The issues he says fall under the direction of Congress, the Treasury, and the Federal Reserve Bank. These include whether the Fed itself should host customer accounts, whether anonymity should be permitted, and what protections users would have in case of a cyber-breach or mistaken transaction. Any policy debate and exploration are separate issues. Discovering what can and can’t be done along with the weaknesses and strengths is the role of the Boston Fed; what to do with that information falls on others.

Around
the World

It’s difficult to have a discussion about any major issue of commerce without looking around the world and seeing what U.S. competitors are up to. The most aggressive mover on the CBDC front is China. The CCP is moving fast to develop its own digital currency, the digital Yuan. At the current pace, the Chinese CBDC will be in use at the 2022 Beijing Olympics.  This alone may force some worldwide use of their digital currency.

For its part, the European Central Bank had this to say, “We have not yet decided whether to issue a digital euro. We are currently in a preparation phase: we’re developing the concept, conducting practical experimentation, listening to the views of the broader public and engaging with stakeholders.” There doesn’t seem to be any urgency in the exploration or adoption of a digital Euro, “We will decide whether to launch a digital euro project towards the middle of 2021, in order to be prepared for the possible issuance of a digital euro at some point in the future,” they said.

 In February 2020, the Central Bank of Brazil (BCB) launched its own official payment network, Pix, which allows instant money transfer and QR code scanning. This digital payment method had its soft launch in November 2020. Brazil has scheduled mass adoption of Pix for this year. 

Washington View

The exploratory push of digital currency technology should not be confused with a push to adopt cashless dollars or other current cryptocurrencies. During the same BIS meeting on March 22, US Fed Chair Powell also had this to say about Bitcoin and other traded cryptocurrencies,” “They’re more of an asset for speculation, so they’re not particularly in use as a means of payment. It’s more a speculative asset. It’s essentially a substitute for gold rather than for the dollar.” So he believes that the current state of non-central bank digital currencies is that they are a gold substitute, not a dollar substitute. Gold is a speculative asset against inflation, civil unrest, and other issues of sovereign risk.

For her part, the former Fed Chair and current Treasury Secretary Janet Yellen spoke a month earlier and had this to say about digital currencies, “To the extent it is used, I fear it’s often for illicit finance. It’s an extremely inefficient way of conducting transactions, and the amount of energy that’s consumed in processing those transactions is staggering.”

It would seem clear from both of these statements that they lean away from any currently traded digital currencies.

Impact of Industries

The Fed and other central banks around the world are giving a lot of attention to digital currencies. China seems intent on developing a standard and introducing a digital Yuan early along with some required use. Brazil has already begun its digital payment system, and companies like Facebook that are financially stronger than many countries have plans of introducing their own crypto to the world. This level of disruption is sure to impact industries. There is no ability to clearly see the future, but assuming in the not-so-distant future many of the world’s transactions take place with a digital currency, these are the impacted industries.

Within financial services, facilitating payments is highly profitable for banks; international transactions generate billions in revenue for financial companies. Digital payments could allow a secure and cheap way of sending payments that cut down on the need for verification from third parties and beat the processing times of current bank transfers. The various cryptocurrencies themselves not tied to a central bank could be the most severe victims. Could it be the current speculative favorites whither? Although when the U.S. went off the gold standard, gold still maintained value, the value of various speculative currencies may quickly be undermined by an official “Fedcoin.” The winners could be blockchain companies and others that adopt the technology for non-currency applications. This could include the travel industry, crowdfunding where it helps with cybersecurity risks, and ridesharing could benefit from a less centralized dispatch system. Trucking could be helped by the technology now most thought of for cryptocurrency tracking — there are currently 500 members of BiTA, the blockchain transportation alliance.  Aerospace and defense companies are working with blockchain technology that has the potential to streamline parts inventory and authentication. Real estate and title issues can be improved with the ledger systems of blockchain to improve efficiency and accuracy.

More directly, a central bank digital currency could make consumers’ everyday transactions easier which by itself is stimulative. Money growth comes from the increased velocity of money. Certainly, an increased ability to transact digitally could be very stimulative throughout the economy.

 

Suggested Reading:


Cryptocurrency Gaining Bank’s Acceptance Backed by the Full Faith and Credit of Blockchain



Is the Small Firm Effect for Microcaps Real? Small Cap Names in a Big Crypto Market

 

 

Sources:

 https://www.coindesk.com/video/the-boston-feds-jim-cunha-cbdcs-are-here-and-theyre-real

https://www.ecb.europa.eu/euro/digital_euro/html/index.en.html

https://www.bcb.gov.br/htms/public/inovtec/Currency-in-the-Digital-Era.pdf

https://www.cbinsights.com/research/industries-disrupted-blockchain/#government

https://www.theguardian.com/business/2018/nov/19/why-central-bank-digital-currencies-will-destroy-bitcoin

Energy Fuels (UUUU)(EFR:CA) – Energy Fuels Restocks its Balance Sheet and Inventories

Tuesday, March 23, 2021

Energy Fuels (UUUU)(EFR:CA)
Energy Fuels Restocks its Balance Sheet and Inventories

As of April 24, 2020, Noble Capital Markets research on Energy Fuels is published under ticker symbols (UUUU and EFR:CA). The price target is in USD and based on ticker symbol UUUU. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Energy Fuels is the largest uranium producer in the U.S. and holds more production capacity and uranium resources than any other U.S. producer. The Company also produces vanadium. Headquartered in Colorado, Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch ISR Facility in Wyoming, and the Alta Mesa ISR Facility in Texas. The producing White Mesa Mill is the only conventional uranium mill in the U.S. and has a licensed capacity of 8 million pounds of U3O8 per year. Nichols Ranch is in production and has a licensed capacity of 2 million pounds of U3O8 per year. Alta Mesa is currently on standby. Energy Fuels also owns several licensed and developed uranium and vanadium mines on standby and other projects in development.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    UUUU reports financial results. As expected, Energy Fuels completed another year of limited production and sales due to depressed uranium prices. On a positive note, losses decreased due to cost reductions and there are signs that uranium prices may be improving. The operating loss for the year was $24.6 million vs. $40.6 million and $34.0 million expected, and EPS was $(0.23) vs. $(0.40) and $(0.28) expected. Call on Tuesday at 4:00 pm ET (888-664-6392).

    The company shored up its balance sheet and appears ready to expand.  Management took advantage of share price strength to raise $30.4 million on its ATM program pushing working capital to $40.2 million ($22.4 million cash/mkt sec). The company has no debt. Both numbers are up sharply from last year and leave Energy Fuels in a good position to weather another year of operating losses if uranium …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Great Lakes Dredge & Dock (GLDD) – Added Awards Announced

Tuesday, March 23, 2021

Great Lakes Dredge & Dock (GLDD)
Added Awards Announced

Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The company only’s operating segments is Dredging. Dredging involves the enhancement or preservation of navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand or rock. Its projects portfolio includes Coastal Restoration, Coastal Protection, Port expansion, and others.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Two major dredging awards announced totaling $90.3 million including the formal announcement on known work and one new award. Yesterday, two major dredging awards for $90.3 million were announced. The awarded work includes: Boston Harbor Navigation Improvement Project-Phase 3 (Capital work for $61.8 million), and Rehabilitation Effort for the Panama City Beaches Coastal Storm Risk Management Project (Coastal Protection for $28.5 million).

    Awards add to the four awards for $60.9 million announced in January to bring 1Q2021 awards to $151.2 million.  Please note that the January awards were included in year-end 2020 backlog. The four awards (three maintenance and one coastal protection) include a total work of $60.9 million in Florida and Georgia. Three of the four awards should be completed in 1Q2021 and the fourth extending out into …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Comstock Mining (LODE) – First International Remediation and Extraction Facility is Now in Production


Comstock and MCU Commence Philippine Mercury Remediation Operations;
First International Remediation and Extraction Facility is Now in Production

 

Virginia City, NV (March 23, 2021) – Comstock Mining Inc. (NYSE: LODE) (“Comstock” and the “Company”) and Mercury Clean Up LLC (“MCU”), announced today that all of the site construction and mercury system set up and testing was completed in their Clean Mercury Remediation Technologies (“CMRT”) joint venture earlier this month with the system going operational last week. This represents the first commercial mercury remediation system in the province of Davao D’ Oro, Philippines, and the foundation for adding additional remediation systems into this unprecedented, eco-system-wide mercury remediation effort in the Philippines and leading achievement for the U.N’s Minamata Convention, the international treaty designed to protect human health and the environment from emissions and releases of mercury and mercury compounds. The international agreement strives to reduce mercury pollution from targeted activities, particularly artisanal and small-scale gold mining, responsible for the major release of mercury to the immediate environment.

Photo accompanying this announcement is available at https://www.comstockmining.com/press-releases/comstock-and-mcu-commence-philippine-mercury-remediation-operations/

“There is a real joy about being back into production, especially when our production cleans, remediates, and restores the environment back into its natural state.” stated Comstock’s Executive Chairman and CEO, Corrado DeGasperis. “This is the first of multiple systems MCU is dedicating to clean up this entire eco-system, not only reviving the 24-kilometer river, but the downstream irrigations, agriculture and communities it previously served. The social impact is incalculable and represents the baseline for mining-related contaminations across the entire country. The Country’s leading environmental regulator stated that the success of this cleanup will set the standard for the rest of country.”

Artisanal and Small-Scale Gold Mining (ASGM) Dilemma

Mercury?dependent ASGM uses a process known as amalgamation to dissolve gold from natural deposits. The amalgam is then typically isolated by hand and then heated to distill the mercury and isolate the gold. Problematically, mercury is hazardous to human health and the environment, where residual ASGM wastes contaminate water and soil and ultimately bioaccumulate into food chains. Mercury risks to children are particularly acute, with mercury emissions from ASGM disabling both physical and mental development. The process was regulated into near extinction by most countries, but upwards of 20 million people still use mercury to mine for gold in more than 70 countries, making mercury pollution from ASGM a U.N. prioritized global issue through the Minamata Convention. The Philippine Naboc River has long been a channel for effluents of mining activities in the area, as evidenced by the high levels of mercury and total suspended solids, according to the Philippine Department of Environment and Natural Resources (DENR), with hundreds of previous processing activities operating on Mt. Diwata without proper tailing ponds, releasing with their toxic, mercury-laden discharges into the Naboc River.

Proprietary Remediation and Extraction Process

The MCU mercury remediation system is the first of several planned by MCU, Comstock and CMRT in the region. Each system is mobile and specifically designed for remote deployment, to remediate mercury from existing amalgamation wastes while extracting residual by-products, including gold, cleaned sand, soil and gravel for commercial use. The mercury wastes are disposed in a safe and compliant manner, thereby repairing and enhancing local ecosystems, while the extracted gold and cleaned by-products provide multiple high-margin revenue streams.

“Each patent-pending core remediation system is expected to produce positive cash flow within just a few months of start-up, with fast full returns on capital deployed, typically in less than 18 months, depending on processing rates and the various by-products extracted from environment,” continued Mr. DeGasperis. “Our plan involves deploying another system this year and several additional systems thereafter, now that the first one is up and running, as we look toward expanding the social impact across the entire district and sustained, positive cash flow growth.”

About Comstock Mining Inc.

Comstock Mining Inc. is an emerging leader in sustainable, mineral development and production of environment-enhancing, increasingly scarce strategic and precious metals, focused on conservation-based waste, high-value, cash-generating, mineral and metals essential to meeting the rapidly increasing demand for clean energy technologies. The Company has extensive, contiguous property in the historic, world-class Comstock and Silver City mining districts (collectively, the “Comstock District”) with fully permitted, metallurgical labs and an operational, mineral processing and beneficiation platform that includes a growing portfolio of mercury remediation and gold extraction facilities.  Additional information on Comstock is available online at www.comstockmining.com.

Forward-Looking Statements

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements, but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: consummation of all pending transactions; project, asset or Company valuations; future industry market conditions; future explorations, acquisitions, investments and asset sales; future performance of and closings under various agreements; future changes in our exploration activities; future estimated mineral resources; future prices and sales of, and demand for, our products; future impacts of land entitlements and uses; future permitting activities and needs therefor; future production capacity and operations; future operating and overhead costs; future capital expenditures and their impact on us; future impacts of operational and management changes (including changes in the board of directors); future changes in business strategies, planning and tactics and impacts of recent or future changes; future employment and contributions of personnel, including consultants; future land sales, investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives; the nature and timing of and accounting for restructuring charges and derivative liabilities and the impact thereof; contingencies; future environmental compliance and changes in the regulatory environment; future offerings of equity or debt securities; asset sales and associated costs; future working capital, costs, revenues, business opportunities, debt levels, cash flows, margins, earnings and growth. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: counterparty risks; capital markets’ valuation and pricing risks; adverse effects of climate changes or natural disasters; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration or mining activities; contests over title to properties; potential dilution to our stockholders from our stock issuances and recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting businesses; permitting constraints or delays; decisions regarding business opportunities that may be presented to, or pursued by, us or others; the impact of, or the non-performance by parties under agreements relating to, acquisitions, joint ventures, strategic alliances, business combinations, asset sales, leases, options and investments to which we may be party; changes in the United States or other monetary or fiscal policies or regulations; interruptions in production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, cyanide, water, diesel fuel and electricity); changes in generally accepted accounting principles; adverse effects of terrorism and geopolitical events; potential inability to implement business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors or others; assertion of claims, lawsuits and proceedings; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the SEC; potential inability to list our securities on any securities exchange or market; inability to maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund or any other issuer.

Contact information

Comstock Mining Inc.
117 American Flat Rd
PO Box 1118
Virginia City, NV 89440
http://www.comstockmining.com

Corrado De Gasperis
Executive Chairman & CEO
Tel (775) 847-4755
degasperis@comstockmining.com

Zach Spencer
Director of External Relations
Tel (775) 847-5272 ext.151
questions@comstockmining.com

Source: Comstock Mining

Research coverage of Comstock Mining (LODE) on Channelchek is provided by Noble Capital Markets, Inc. Please refer to the research disclosures on the most recent LODE report for more information.

Release – electroCore Inc. (ECOR) – Announces Exclusive Distribution Agreement with Silvert Medical Nv-Sa. For Western Europe


electroCore, Inc. Announces Exclusive Distribution Agreement with Silvert Medical Nv-Sa. For Western Europe

 

ROCKAWAY, N.J.
March 23, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with Silvert Medical Nv-Sa. (“Silvert Medical”) whereby Silvert Medical will serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) to patients suffering from primary headache disorders in 
Belgium, Luxembourg, 
the Netherlands, and 
France.

“Silvert Medical is proud and excited to represent electroCore’s non-invasive and drug-free medical treatment for chronic migraine and cluster headache. gammaCore Sapphire matches our mission of ’Innovation and Solutions for Better Patient Care’ perfectly,” said  Eric Silvert, Owner and Managing Director of Silvert Medical. “Our long-term expertise in pain management and neuromodulation combined with our access to key opinion leaders within our territories such as 
Belgium, Luxembourg, 
the Netherlands, and 
France will help establish a solid and lasting business relationship.”

“We are delighted to collaborate with Silvert Medical as we continue to expand the geographical coverage of our nVNS therapy amongst patients suffering with migraine and cluster headache,” said Iain Strickland, electroCore’s Vice President of European Operations. “Silvert Medical is an experienced medical device supplier and we look forward to supporting them in our common goal of introducing our nVNS therapy, gammaCore Sapphire, in new Western European territories.”

The initial term of the agreement is three years, and it contains customary terms and conditions, including minimum purchase commitments.

About Silvert Medical Nv-Sa.

Belgium, Silvert Medical Nv-Sa brings a wealth of experience, knowledge and keen responsiveness as a medical device supplier and provides innovative and disruptive medical device technologies to the 
Belgium, Luxembourg, 
the Netherlands, and 
France clinical and patient community.

For more information, visit http://www.silvertmedical.com/

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are for the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCore™

gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in 
the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the 
European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

gammaCore is contraindicated for patients with:

  • An active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  • A metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
  • An open wound, rash, infection, swelling, cut, sore, drug patch, or surgical scar(s) on the neck at the treatment location

Safety and efficacy of gammaCore have not been evaluated in the following patients:

  • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  • Pediatric patients (younger than 12 years)
  • Pregnant women
  • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

In the US, the FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders such as acute respiratory stress disorder associated with COVID-19.

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects in 
Western Europe and other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the 
SEC available at www.sec.gov.

Investors:
Rich Cockrell
CG Capital
404-975-4837
ich@cg.capital

Media Contact:
Summer Diaz
electroCore
816-401-6333
summer.diaz@electrocore.com

Source: electroCore, Inc.

QuickChek – March 22, 2021



Gevo Hires Dr. Paul Bloom as Chief Technology Officer and Chief Innovation Officer

Gevo announced that Dr. Paul Bloom has joined Gevo as its Chief Technology Officer and Chief Innovation Officer.

Research, News & Market Data on Gevo

Watch recent presentation from NobleCon17



Comtech Telecommunications Corp. Awarded Follow-on Order for More Than $1.0 Million for Military X-band SSPAs

Comtech Telecommunications announced it received a contract valued at more than $1.0 million for X-band SSPA/BUCs for transportable military satellite communications ground systems.

Research, News & Market Data on Comtech Telecommunications

Watch recent presentation from NobleCon17



Bunker Hill Announces Updated Mineral Resource and Identifies New Silver Exploration Targets

Bunker Hill Mining reported a significant resource increase at Bunker Hill Mine located in Idaho’s Silver Valley, USA.

News & Market Data on Bunker Hill Mining




Energy Fuels Announces 2020 Results

Energy Fuels announced its financial results for the year ended December 31, 2020.

Research, News & Market Data on Energy Fuels

Watch recent presentation from NobleCon17

Stay up to date. Follow us:

Release – Bunker Hill Mining (BHLL)(BNKR:CA) – Announces Updated Mineral Resource and Identifies New Silver Exploration Targets


Bunker Hill Announces Updated Mineral Resource and Identifies New Silver Exploration Targets

 

HIGHLIGHTS:

  • Previous 8.8Mt Inferred resource
    significantly upgraded, supporting the rapid restart program:
    • Indicated resource of 4.4Mt
      containing 3.03Moz of silver, 487M lb of zinc, and 176M lb of lead
    • Inferred resource of 5.6Mt
      containing 8.3Moz of silver, 548M lb of zinc, and 312M lb of lead
  • UTZ added new resource with
    successful silver exploration drilling
  • The PEA remains on track for
    completion in early Q2-2021
  • New, near surface silver
    exploration targets to be evaluated in current drilling campaign

TORONTO, March 22, 2021 (GLOBE NEWSWIRE) — Bunker Hill Mining Corporation (the “Company”) (CSE: BNKR) is pleased to report a significant resource increase at Bunker Hill Mine located in Idaho’s Silver Valley, USA. This underpins the Preliminary Economic Assessment (“PEA”), aimed the mine’s rapid restart potential, due to be published in early Q2-2021.

Sam Ash, CEO of Bunker Hill Mining, stated: “We are excited to see the results of our drilling campaign and continued digitization realized in this significant upgrade of the resource at Bunker Hill, building on the maiden resource we published less than a year ago.  This demonstrates the mine’s outstanding mineral potential, which we expect to be reflected in the PEA assessing a rapid restart. This remains on track for delivery in early April. As part of the on-going campaign to add more silver to our resources, we have also identified some exciting new silver exploration targets in the upper levels of the mine which will be evaluated by drilling over the next few weeks”.

The on-going digital modernization program has yielded a three-dimensional model, defining nearly 100 years of mining voids and geology, which increases confidence in the estimation of mineralization. Additional drilling, modern data collection and assaying, quality assurance and quality control protocols, as well as the verification channel sampling program of 2020 has provided the necessary information to increase the confidence and classification of the Newgard, Quill and UTZ mineral resource estimates. The preponderance of data has converted approximately seventy-seven percent (77%) of the Bunker Hill Mineral Resource to the Indicated Mineral Resource category.

The Bunker Hill Mineral Resource, effective March 19, 2021, reported at a zinc cutoff grade of 3.3% is described below:

Bunker Hill Resource Table

Zinc Resources

K Tons

Pb%

Ag opt

Zn%

Indicated

4,410

2.00

0.69

5.52

Inferred

4,569

1.67

0.83

5.66

Lead-Silver Resources

K Tons

Pb%

Ag opt

Zn%

Indicated

Inferred

1,050

7.56

4.28

1.50

Total Resources

K Tons

Pb%

Ag opt

Zn%

Indicated

4,410

2.00

0.69

5.52

Inferred

5,618

2.77

1.48

4.88

Mineral Resources are reported at a zinc cutoff grade of 3.3%. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. Mineral Resources are reported in situ and undiluted. Mineral Resources meet the reasonable prospects of eventual economic extraction due to the fact that the entire vertical extents of the mineralization have been developed on mining levels every two-hundred feet. Newgard and Quill were being actively exploited and developed prior to the shutdown of mining operations in 1991. High grade capping was applied to the assays prior to grade estimation. Grades are estimated using Inverse Distance Cubed (ID3) interpolation techniques. Grades were estimated into a regularized 5 ft x 5 ft x 5 ft block model. A bull density of 11.3 cubic feet per ton was applied to the entire mineral resource based upon historic density values from production records at Bunker Hill. Two-hundred sixty-one (261) drillholes, totaling 29,380-feet, containing 5,720 Pb, Zn and Ag assays were used in the determination of mineralization. Assays were composited to 4,483 5-foot composites. Additionally, 4,545 historic production car samples and 394 channel sample verification samples were used for the resource estimate. Historic mining voids, stopes and development drifting have been accounted for in the resource estimate.

Figure 1: Oblique View of
UTZ, Newgard and Quill Mineral Zones Showing Indicated and Inferred
Mineralization

https://www.globenewswire.com/NewsRoom/AttachmentNg/5e639480-0046-4f96-b5e6-6a71046ab75f

Significant New Silver
Exploration Target Identified

New interpretation and analysis based on developments in the geologic model have identified an exciting new silver exploration opportunity in the hanging wall of the Cate Fault in the upper areas of the Bunker Hill Mine.

Silver production at Bunker Hill came largely from discrete Galena-Quartz Veins that formed ore shoots hosted in preferable quartzite beds of the Revett formation. The vein segments are bounded by large normal faults such as the Dull, Kruger and Sullivan Faults, which have down-dropped large blocks of the stratigraphy and veins down to the south, with >4000 ft of collective displacement. The more recent Cate Thrust Fault has then bisected this package of rocks, shifting rocks above the fault >500 ft up to the north.

The 3D modeling has allowed Bunker Hill geologists to project these vein segments back to their position at time of emplacement. The presence of high-grade silver veins such as the historically mined Sierra Nevada Vein in the hanging wall of the Cate Fault demonstrate that the width of the mineralizing system has not been discovered and the southern margin is unknown. The similar grades, thickness and mineralogy of the vein segments across the earlier normal faults shows that the vertical extent of the system was likely at least 4x the down-dip length of the individual veins. A similar set of normal faults, such as the Buckeye Fault, with significant down-to-the-south displacement also exists in the hanging wall of the Cate fault, with Ag-Pb-Zn mineralization indicated by historic and recent drilling in the hanging wall, or down-dropped portions of these faults.

Figure 2: Hanging Wall of
Cate Fault

https://www.globenewswire.com/NewsRoom/AttachmentNg/2a09189f-10be-49f0-884e-c1df4a2b7e1d

To summarize, none of the major faults that were historically thought as controlling ore emplacement actually bound the mineralizing system, and the entire Property is fully within the elevation and mineralogical zonation leading to silver, lead and zinc deposition.

The Cate Fault was the limit of most early mining in the upper parts of Bunker Hill, and it wasn’t until the 1960’s that it was recognized as having post-mineral offset. A few of the first core holes ever drilled in Bunker Hill in 1898 from the 5 Level were directed past the Cate and Buckeye Faults, with impressive results including 12′ @ 42.7% Pb and 18.6 opt Ag in DH-4, but mining largely shifted to below the 9 level after the Kellogg Tunnel was completed, and these holes were never followed up on. Bunker Hill is currently drilling to test these targets, and the holes are intersecting encouraging structures and lithologies similar to what has been modeled. Any mineralization encountered in these holes will be an entirely new vein system for Bunker Hill, not defined, named, mined or incorporated in any prior mine plans or resource estimates. Drill holes have been planned to systematically offset any successful intercepts in the first holes, and drill stations are being prepared to test these targets at appropriate angles and reduced distances. The locations of the targets are such that any mineralization defined with successful drilling could be rapidly incorporated in an update to mine plans or mineral resources.

Figure 3: Planned Drill
Holes from 5 Level at Cate and Buckeye Faults

https://www.globenewswire.com/NewsRoom/AttachmentNg/b9ae78a0-bbf0-427c-a064-0d482390eec3

Note: The reader is cautioned that these are exploration-stage targets, which is speculative in nature, and there is no guarantee of positive drill results defining any economic mineralization.

A video summarizing the digitization process can be viewed at the following link https://youtu.be/8X3FrWfbGl4?t=229 . In addition, further information is available on our newly launched website.

Recent drill results are presented in the tables below.

ZINC INTERCEPTS

Hole 7046

7046

From

To

M

ZnEq (%)

g/t Ag

%Pb

%Zn

99.5

119.0

19.5

4.3

15.7

1.4

2.8

Including

99.5

100.7

1.2

7.9

24

1.8

5.9

103.3

103.8

0.5

12.5

59

4.7

7.2

105.8

107.3

1.5

7.0

21

1.9

5.0

108.5

109.7

1.2

5.5

16

1.5

3.9

113.8

115.2

1.4

10.2

41

4.3

5.7

Hole 7047

7047

From

To

M

ZnEq (%)

g/t Ag

%Pb

%Zn

92.2

93.1

0.9

9.7

9

0.4

9.1

105.6

106.7

1.1

4.8

10

0.6

4.1

Hole 7052

7052

From

To

M

ZnEq (%)

g/t Ag

%Pb

%Zn

20.1

23.6

3.5

2.1

11.3

0.6

1.3

Including

20.1

22.5

21

23.6

9

1.1

4.4

2.9

16

22

0.8

1.3

3.4

1.4

 

7052

From

To

M

ZnEq (%)

g/t Ag

%Pb

%Zn

37.2

44.5

7.3

2.4

7.8

0.5

1.8

Including

37.2

38.1

0.9

2.8

18

1.5

1.1

39.5

39.8

0.3

9.2

26

2.0

6.9

42.2

43.3

1.1

5.7

10

0.5

5.1

43.3

44.5

1.2

4.0

12

0.7

3.2

Hole 7055A

7055A

From

To

M

ZnEq (%)

g/t Ag

%Pb

%Zn

19.4

20.4

1.0

25.0

105

7.8

16.1

Hole 7061

7061

From

To

M

ZnEq (%)

g/t Ag

%Pb

%Zn

11.9

18.1

6.2

7.3

22.6

1.7

5.5

Including

11.9

12.6

0.7

13.5

29

1.7

11.5

14.2

15.2

1

5.4

38

3.5

1.7

15.2

16.5

1.3

6.6

17

1.3

5.2

16.9

17.7

0.8

18.0

48

3.1

14.3

17.7

18.1

0.4

13.4

20

1.4

11.7

SILVER INTERCEPTS

Hole 7046

7046

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

134.1

159.4

25.3

92.3

12.8

1.0

1.2

Including

138.1

139.5

1.4

255.4

38

2.5

3.4

142.6

143.7

1.1

180.5

26

2.6

1.8

148.4

149.3

0.9

212.5

24

2.5

2.8

158.9

159.4

0.5

332.4

65

3.4

4.0

Hole 7052

7052

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

15.7

17.7

2

85.8

15.5

1.3

0.7

Including

15.7

17.1

16.0

17.7

0.3

0.6

219.5

151.5

34

30

2.6

2.8

2.6

0.8

Hole 7052

7052

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

32.9

33.5

0.6

348.3

43

3.98

4.2

Hole 7054

7054

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

0.9

4.2

3.3

337.1

81.7

7.5

0.4

Including

0.9

2.0

1.1

212

51

5

0.1

2.0

2.4

0.4

282.5

72

6.5

0.1

2.4

3.6

1.1

610

149

13.7

0.7

Hole 7054

7054

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

15.8

16.4

0.6

328.9

86

7.6

0.1

Hole 7055A

7055A

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

1.5

2.3

0.8

361.5

92

8.5

0.1

Hole 7064

7064

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

131.7

132.4

0.7

357.2

138

7.0

0.01

*Due to poor recovery and for QA/QC purposes in portions of holes 7054, 7056 and 7063 and for QA/QC purposes, the company chose to report assay results based only
on recovered
footage. Drilled footage is NOT the reported width of the intercepts.

(Reported widths are
intercepted ore lengths and not true widths, as relationships with
intercepted structures and contacts vary. Prices used to calculate Ag and Zn
Eq are as follows: Zn=$1.16/lb, Pb=$0.92/lb, Ag=$20/oz.)

Upcoming Events:

Alliance Global Partners
(A.G.P) Mining Series Fireside Chat

March 23, 2021 @ 8:00am PT / 11:00am ET
Join Us: REGISTER NOW

Mining & Money Online
Connect

March 24, 2021 @ 10:00am PT / 1:00pm ET
Join Us: REGISTER NOW

Technical Information

The diamond drilling program used HQ-size core.  Bunker Hill followed standard QA/QC practices to ensure the integrity of the core and sample preparation through to delivery of the samples to the assay lab.  The drill core was stored in a secure facility, photographed, logged and sampled based on lithologic and mineralogical interpretations.  Standards of certified reference materials, field duplicates and blanks were inserted as samples shipped with the core samples to the lab.

ALS Global was used to provide analytical services and all results comply with both NI 43-101 and industry standards. ALS Global holds an industry standard ISO 17025 accreditation, specifying general requirements for laboratory performance.

The Company advises that it does not propose to base its production decision on a feasibility study of mineral reserves, demonstrating economic and technical viability, and, as a result, there may be an increased uncertainty of achieving any particular level of recovery of minerals or the cost of such recovery, including increased risks associated with developing a commercially mineable deposit. Historically, such projects have a higher risk of economic and technical failure. There is no guarantee that production will begin as anticipated or at all or that anticipated production costs will be achieved. The Company further cautions that a PEA is preliminary in nature. No mining study has been completed. Mineral resources are not mineral reserves and do not have demonstrated economic viability. There is no certainty that the PEA will be realized.

Qualified Person

Mr. Scott E. Wilson, CPG, President of Resource Development Associates Inc. and a consultant to the Company, is an Independent “Qualified Person” as defined by NI 43-101 and is acting at the Qualified Person for the Company. He has reviewed and approved the technical information summarized in this news release.

About Bunker Hill Mining
Corp.

Under new Idaho-based leadership the Bunker Hill Mining Corp, intends to sustainably restart and develop the Bunker Hill Mine as the first step in consolidating a portfolio of North American precious-metal assets with a focus on silver. Information about the Company is available on its website, www.bunkerhillmining.com, or within the SEDAR and EDGAR databases.

For additional information contact:

Sam Ash, President and Chief Executive Officer
+1 208 786 6999
sa@bunkerhillmining.com

Cautionary Statements

Certain statements in this
news release are forward-looking and involve a number of risks and uncertainties.
Such forward-looking statements are within the meaning of that term in
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, as well as within the meaning of
the phrase ‘forward-looking information’ in the Canadian Securities
Administrators’ National Instrument 51-102 – Continuous Disclosure
Obligations. Forward-looking statements are not comprised of historical
facts. Forward-looking statements include estimates and statements that describe
the Company’s future plans, objectives or goals, including words to the
effect that the Company or management expects a stated condition or result to
occur. Forward-looking statements may be identified by such terms as
“believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”,
“will”, or “plan”. Since forward-looking statements are based on assumptions
and address future events and conditions, by their very nature they involve
inherent risks and uncertainties. Although these statements are based on
information currently available to the Company, the Company provides no
assurance that actual results will meet management’s expectations. Risks,
uncertainties and other factors involved with forward-looking information
could cause actual events, results, performance, prospects and opportunities
to differ materially from those expressed or implied by such forward-looking
information. Forward looking information in this news release includes, but
is not limited to, the Company’s intentions regarding its objectives, goals
or future plans and statements. Factors that could cause actual results to
differ materially from such forward-looking information include, but are not
limited to: the ability to predict and counteract the effects of COVID-19 on
the business of the Company, including but not limited to the effects of
COVID-19 on the price of commodities, capital market conditions, restriction
on labour and international travel and supply chains; failure to identify
mineral resources; failure to convert estimated mineral resources to
reserves; the inability to complete a feasibility study which recommends a
production decision; the preliminary nature of metallurgical test results;
delays in obtaining or failures to obtain required governmental, environmental
or other project approvals; political risks; changes in equity markets;
uncertainties relating to the availability and costs of financing needed in
the future; the inability of the Company to budget and manage its liquidity
in light of the failure to obtain additional financing, including the ability
of the Company to complete the payments pursuant to the terms of the
agreement to acquire the Bunker Hill Mine Complex; inflation; changes in
exchange rates; fluctuations in commodity prices; delays in the development
of projects; capital, operating and reclamation costs varying significantly
from estimates and the other risks involved in the mineral exploration and
development industry; and those risks set out in the Company’s public
documents filed on SEDAR. Although the Company believes that the assumptions
and factors used in preparing the forward-looking information in this news
release are reasonable, undue reliance should not be placed on such
information, which only applies as of the date of this news release, and no
assurance can be given that such events will occur in the disclosed time
frames or at all. The Company disclaims any intention or obligation to update
or revise any forward-looking information, whether as a result of new information,
future events or otherwise, other than as required by law. No stock exchange,
securities commission or other regulatory authority has approved or
disapproved the information contained herein.

Cautionary Note to United
States Investors Concerning Estimates of Measured, Indicated and Inferred
Resources

This press release has
been prepared in accordance with the requirements of the securities laws in
effect in Canada, which differ from the requirements of U.S. securities laws.
Unless otherwise indicated, all resource and reserve estimates included in
this press release have been disclosed in accordance with NI 43-101 and the
Canadian Institute of Mining, Metallurgy, and Petroleum Definition Standards
on Mineral Resources and Mineral Reserves. NI 43-101 is a rule developed by
the Canadian Securities Administrators which establishes standards for all
public disclosure an issuer makes of scientific and technical information
concerning mineral projects. Canadian disclosure standards, including NI
43-101, differ significantly from the requirements of the United States
Securities and Exchange Commission (“SEC”), and resource and reserve
information contained in this press release may not be comparable to similar
information disclosed by U.S. companies. In particular, and without limiting
the generality of the foregoing, the term “resource” does not equate to the
term “reserves”. Under U.S. standards, mineralization may not be classified
as a “reserve” unless the determination has been made that the mineralization
could be economically and legally produced or extracted at the time the
reserve determination is made. The SEC’s disclosure standards normally do not
permit the inclusion of information concerning “measured mineral resources”,
“indicated mineral resources” or “inferred mineral resources” or other
descriptions of the amount of mineralization in mineral deposits that do not
constitute “reserves” by U.S. standards in documents filed with the SEC.
Investors are cautioned not to assume that any part or all of mineral
deposits in these categories will ever be converted into reserves. U.S.
investors should also understand that “inferred mineral resources” have a
great amount of uncertainty as to their existence and great uncertainty as to
their economic and legal feasibility. It cannot be assumed that all or any
part of an “inferred mineral resource” will ever be upgraded to a higher
category. Investors are cautioned not to assume that all or any part of an
“inferred mineral resource” exists or is economically or legally mineable.
Disclosure of “contained ounces” in a resource is permitted disclosure under
Canadian regulations; however, the SEC normally only permits issuers to
report mineralization that does not constitute “reserves” by SEC standards as
in-place tonnage and grade without reference to unit measures. The
requirements of NI 43-101 for disclosure of “reserves” are also not the same
as those of the SEC, and reserves disclosed by the Company in accordance with
NI 43-101 may not qualify as “reserves” under SEC standards. Accordingly,
information concerning mineral deposits contained in our website may not be
comparable with information made public by companies that report in
accordance with U.S. standards.

Source: Bunker Hill Mining

Sierra Metals (SMTS)(SMT:CA) – Solid 2020 Performance 2021 Estimates Largely Unchanged

Monday, March 22, 2021

Sierra Metals (SMTS)(SMT:CA)
Solid 2020 Performance; 2021 Estimates Largely Unchanged

As of April 24, 2020, Noble Capital Markets research on Sierra Metals is published under ticker symbols (SMTS and SMT:CA). The price target is in USD and based on ticker symbol SMTS. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Sierra Metals Inc is a precious and base metals producer in Latin America. The company acquires, explores, extracts, and produces mineral concentrates consisting of silver, copper, lead, zinc and gold in Mexico and Peru. Its activity includes the operation of the Yauricocha Mine in Peru, and the Bolivar and Cusi mines in Mexico. Yauricocha is an underground polymetallic mine using the sublevel block caving and cut-and-fill mining methods. Bolivar is a copper-silver-zinc-gold underground mine using room-and-pillar mining method. The majority of the revenue is earned by selling of the mineral concentrates to its customers in Peru.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Full year financial results. Sierra Metals reported full year 2020 adjusted net income attributable to shareholders of $29.6 million, or $0.18 per share, compared with $13.9 million, or $0.08 per share, in 2019. Adjusted EBITDA increased 48.6% to $97.0 million compared with $65.3 million in the prior year. Our EPS and EBITDA estimates were $0.20 and $101.3 million. Variances to our estimates were attributed to modestly higher expense. Despite the impact of government-mandated shutdowns during the second quarter and work-flow adjustments due to COVID-19, the company posted strong earnings and cash flow growth in 2020.

    Planned expansions.  Management anticipates receipt in the second quarter of the final permit to increase throughput at the Yauricocha mine by 20% to 3,600 tonnes per day. The company recently published preliminary economic assessments for all three mines which support planned expansions and is working toward completion of preliminary feasibility studies. Longer-term expansions could increase …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Great Lakes Dredge & Dock (GLDD) – A Good Win in Alabama

Monday, March 22, 2021

Great Lakes Dredge & Dock (GLDD)
A Good Win in Alabama

Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The company only’s operating segments is Dredging. Dredging involves the enhancement or preservation of navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand or rock. Its projects portfolio includes Coastal Restoration, Coastal Protection, Port expansion, and others.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Another win…in Alabama. Bids were opened by the USACE late Friday afternoon on the Phase III of Mobile Harbor deepening work. GLDD was the apparent low bidder at $53.9 million, with Manson closely behind at $57.9 million and Weeks lagging at $76.9 million. Interestingly, all of the bids were well below the IGE of $95.7 million. Final award is slated to be announced in late April.

    Solid dredging outlook with backlog at $559 million, and potential infrastructure spending stimulus could create a tailwind.  We would like to correct a misstatement from our last note and highlight that the Boston award of $62 million was included in the 4Q2020 low bids pending award/options total ~$562 million, including $90 million added in January. Two state projects in Louisiana are out for bid …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Eagle Bulk Shipping (EGLE) – ATM Program and Selling Triggered After Strong Stock Move

Monday, March 22, 2021

Eagle Bulk Shipping (EGLE)
ATM Program and Selling Triggered After Strong Stock Move

Eagle Bulk Shipping Inc. is a US-based drybulk owner-operator focused on the Supramax/Ultramax mid-size asset class, which ranges from 50,000 and 65,000 deadweight tons in size; these vessels are equipped with onboard cranes allowing for the self-loading and unloading of cargoes, a feature which distinguishes them from the larger classes of drybulk vessels and provides for greatly enhanced flexibility and versatility- both with respect to cargo diversity and port accessibility. The Company transports a broad range of major and minor bulk cargoes around the world, including coal, grain, ore, pet coke, cement, and fertilizer. Eagle operates out of three offices, Stamford (headquarters), Singapore, and Hamburg, and performs all aspects of vessel management in-house including: commercial, operational, technical, and strategic.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    ATM program seems well timed. After more than doubling this year, the move to establish an ATM program of $50 million seemed logical, and equity-funded acquisitions could have a positive impact.

    No surprise that the largest shareholder started selling.  Bad news, good news, who knows? As we expected, the strong stock price move (and maybe the ATM program) also triggered selling by the largest shareholder. Filings last week indicated that selling started on March 10th and a total of ~275k shares were sold at an average price of $38.47/share over seven trading days. We would not be surprised …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.